#45
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Scientists have unlocked ancient cannabis enzymes that could make it far easier to produce CBC, a promising anti-inflammatory cannabinoid that today’s plants can’t make in large quantities.
Researchers at Wageningen University reconstructed extinct cannabinoid-producing enzymes that were active millions of years ago. These ancestral enzymes are ‘generalists’—capable of producing THC, CBD, and CBC simultaneously, unlike modern specialized enzymes. They’re more robust and easier to produce in microorganisms like yeast, opening the door to efficient biotechnological cannabinoid production. One enzyme is especially good at making CBC, a cannabinoid with anti-inflammatory properties that no existing plant produces in high quantities.
“This is exactly the kind of research that could deliver the next generation of plant-based anti-inflammatory medicines,if regulators don’t kill the science before it reaches patients.”
PREHISTORIC ENZYMES, FUTURE MEDICINE: What Wageningen’s Discovery Means for Cannabinoids
In one of the most fascinating cannabinoid studies of the year, researchers at Wageningen University reconstructed enzymes that haven’t existed for millions of years—and discovered they may be more useful than their modern descendants.
Here’s the background: in today’s cannabis plants, THC, CBD, and CBC are each produced by dedicated, highly specialized enzymes. One enzyme per compound. The Wageningen team used ancestral sequence reconstruction—analyzing DNA from modern plants to predict what ancient enzymes looked like—and then resurrected them in the laboratory.
What they found was remarkable. The earliest cannabinoid-producing enzymes were generalists, capable of producing multiple compounds simultaneously from a single precursor. A single ancestral enzyme could generate THC, CBD, and CBC at once.
This matters for two reasons. First, these ancient enzymes proved easier to produce in microorganisms like yeast than their modern counterparts. That’s directly relevant to the growing field of biotechnological cannabinoid production, which promises consistency, scale, and independence from agricultural variability.
Second, one reconstructed enzyme is exceptionally good at producing CBC—a cannabinoid known for anti-inflammatory and analgesic properties that no existing cannabis plant produces in high quantities. Introducing this enzyme into a cannabis plant could lead to entirely new medicinal varieties.
Evolution’s rough drafts, it turns out, may be medicine’s best tools.
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →